Trial Profile
A Phase 1, Open Label, Randomized, Two Part Study to Evaluate the Pharmacokinetic Exposure of a Once-Daily (QD) Apremilast Formulation Relative to the Twice-Daily (BID) Reference Immediate Release (IR) Tablet and the Effect of Food on the QD Apremilast Formulation in Healthy Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Apremilast (Primary) ; Apremilast
- Indications Ankylosing spondylitis; Atopic dermatitis; Behcet's syndrome; Bullous pemphigoid; Eczema; Female genital diseases; Hidradenitis suppurativa; Palmoplantar pustulosis; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Amgen; Celgene Corporation
- 02 Mar 2017 Status changed from not yet recruiting to completed.
- 24 May 2016 New trial record